Skip to search formSkip to main contentSkip to account menu

LBH589

Known as: (2E)-N-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)prop-2-enamide, LBH 589, NVP-LBH589 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

panobinostat

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS patients
Phase 2 study of oral panobinostat (LBH589) with or without erythropoietin in heavily transfusion-dependent IPSS low or int-1 MDS… 
2014
2014
Use of the 46/1 haplotype to model JAK2V617F clonal architecture in PV patients: clonal evolution and impact of IFNα treatment
Use of the 46/1 haplotype to model JAK2 V617F clonal architecture in PV patients: clonal evolution and impact of IFNα treatment 
Highly Cited
2012
Highly Cited
2012
Downregulation of HMGA2 by the pan-deacetylase inhibitor panobinostat is dependent on hsa-let-7b expression in liver cancer cell lines.
2012
2012
A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors
SummaryObjective The objective was to determine the maximum tolerated dose and the dose-limiting toxicity of panobinostat (LBH589… 
2012
2012
The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin
Purpose: We have previously shown the use of the insulin-like growth factor type 1 receptor tyrosine kinase (IGF-1RTK) inhibitor… 
Highly Cited
2010
Highly Cited
2010
The HDAC inhibitor LBH589 (panobinostat) is an inhibitory modulator of aromatase gene expression
Aromatase converts androgens to estrogens. Although third-generation aromatase inhibitors (AIs) are important drugs in hormonal… 
2010
2010
The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS)
New drugs with anti-tumor activity, also able to modify the expression of selected molecules, are under evaluation in breast… 
2009
2009
A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).
Abstract 308 Background: Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by progressive constitutional… 
2009
2009
A Phase I Study of Oral Melphalan Combined with LBH589 for Patients with Relapsed or Refractory Multiple Myeloma (MM).
Abstract 1855 Poster Board I-881 We and others have shown that LBH589, a potent histone deacetylase inhibitor (HDACi… 
2007
2007
Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589, a novel deacetylase (DAC) inhibitor given intravenously on a new once weekly schedule
14019 Background: LBH589 is a novel deacetylase inhibitor that inhibits proliferation of tumor cells at nanomolar levels. This… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)